Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.

Autor:	Gopalakrishnan, Sathej, Polepally, Akshanth, Mensing, Sven, Khatri, Amit, Menon, Rajeev, Gopalakrishnan, Sathej M, Polepally, Akshanth R, Menon, Rajeev M
Předmět:	PHARMACOKINETICS RITONAVIR ANTIVIRAL agents JAPANESE people CLINICAL trials HEPATITIS C virus DISEASES AMIDES BIOLOGICAL models BIOTRANSFORMATION (Metabolism) COMBINATION drug therapy COMPARATIVE studies HEPATITIS viruses HYDROCARBONS RESEARCH methodology MEDICAL cooperation KIDNEY failure RESEARCH SEX distribution EVALUATION research FIBROSIS BLIND experiment ACYCLIC acids CHRONIC hepatitis C GENOTYPES THERAPEUTICS
Zdroj:	Clinical Pharmacokinetics; Jan2017, Vol. 56 Issue 1, p1-10, 10p
Abstrakt:	Background and Objective: Hepatitis C virus (HCV) infection is of considerable clinical concern in Japan. We modeled the population pharmacokinetics of an oral interferon-free, direct-acting antiviral agent (DAA) regimen (i.e., the 2D regimen) recently approved for the treatment of chronic HCV genotype 1 infection as a new option for affected Japanese patients.Methods: Using data from a phase III clinical trial (GIFT-I) that enrolled Japanese patients with HCV genotype 1b infection, population pharmacokinetic models were developed for the drugs that comprise the 2D regimen: paritaprevir, ombitasvir, and ritonavir. Demographic and clinical covariates with potential to influence 2D pharmacokinetics were evaluated for their effects on drug exposures. Proposed models were assessed using goodness-of-fit plots, visual predictive checks, and bootstrap evaluations.Results: One-compartment models with first-order absorption and elimination adequately described the population pharmacokinetics of paritaprevir, ombitasvir, and ritonavir. On average, patients with cirrhosis had approximately 95-145 % higher, 19-24 % lower, and 58-68 % higher exposures of paritaprevir, ombitasvir, and ritonavir, respectively. Female patients had 58-81 % higher ombitasvir exposures, whereas patients with mild renal impairment (creatinine clearance 75 mL/min) had 9-14 % higher ombitasvir exposures than did patients with normal renal function (creatinine clearance 105 mL/min). The DAA exposure values were comparable between responders and non-responders.Conclusion: Population pharmacokinetic modeling did not reveal any patient-related or clinical parameters that would require dose adjustment of the 2D regimen when used for the treatment of HCV genotype 1b infection in Japanese patients. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink